gms | German Medical Science

70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

12.05. - 15.05.2019, Würzburg

Bcl-2/Bcl-xL inhibition synergistically enhances the anti-neoplastic activity of CUSP9v3 against glioblastoma cells in vitro

Synergistische Verstärkung der anti-neoplastischen Aktivität von CUSP9v3 gegen Glioblastomzellen durch Hemmung von Bcl-2/Bcl-xL in vitro

Meeting Abstract

  • Marc-Eric Halatsch - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • Richard Eric Kast - IIAIGC Study Center, Burlington, VT, United States
  • Annika Dwucet - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • Michal Hlavac - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • Tim Heiland - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • Mike-Andrew Westhoff - Universitätsklinikum Ulm, Klinik für Pädiatrie, Ulm, Deutschland
  • Markus David Siegelin - Columbia University Medical Center, Department of Pathology and Cell Biology, New York, NY, United States
  • Christian Rainer Wirtz - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland
  • presenting/speaker Georg Karpel-Massler - Universitätsklinikum Ulm, Neurochirurgische Klinik, Ulm, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie. Würzburg, 12.-15.05.2019. Düsseldorf: German Medical Science GMS Publishing House; 2019. DocP053

doi: 10.3205/19dgnc391, urn:nbn:de:0183-19dgnc3913

Veröffentlicht: 8. Mai 2019

© 2019 Halatsch et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: Repurposing represents a promising approach to safely accelerate the clinical application of therapeutics with anti-cancer activity. In this study, we examined whether inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL enhances the biological effects of the repurposed CUSP9v3 regimen in an in vitro setting of glioblastoma.

Methods: We applied MTT assays to assess cellular proliferation. Annexin V/PI and TMRE staining were used to examine apoptosis. Western blotting, RT-PCR and specific knockdown experiments using siRNA were employed to examine molecular mechanisms of action.

Results: Bcl-2/Bcl-xL inhibition yielded synergistic anti-proliferative effects across a wide panel of established and primary cultured glioblastoma cells when combined with CUSP9v3 which had been reduced to only one tenth of its original concentration (CUSP9v3 1/10). The combination treatment also led to enhanced apoptosis with loss of mitochondrial membrane potential and activation of caspases. On the molecular level, CUSP9v3 1/10 counteracted ABT263-mediated upregulation of Mcl-1 and led to suppression of Bcl-xL. Silencing of Mcl-1 enhanced ABT263-mediated apoptosis, indicating that Mcl-1 is crucial for the induction of cell death conveyed by the combination treatment. Levels of Mcl-1 mRNA were not decreased following combination therapy, and co-treatment with cycloheximide showed reduced protein stability, pointing towards a post-translational mechanism of action.

Conclusion: These data suggest that Bcl-2/Bcl-xL inhibition enhances the susceptibility of glioblastoma cells towards CUSP9v3, allowing dramatic dose reduction and potentially decreased toxicity when applied clinically. A clinical trial involving the original CUSPv3 doses is currently ongoing in our institution (NCT02770378). The Bcl-2/Bcl-xL inhibitor ABT263 is used in clinical trials and might represent a valuable adjunct to CUSPv3.